Effect of cyclosporine on HMG-CoA reductase, cholesterol 7α- hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions

Journal of Pharmacology and Experimental Therapeutics

Volumn 294, Issue 2, 2000, Pages 778-783

  Vaziri, Nosratola D ^a,b   Liang, Kaihui ^a   Azad, Habib ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; PLACEBO; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; ENZYME ACTIVITY; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN METABOLISM; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SKELETAL MUSCLE; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ADIPOSE TISSUE; ANIMALS; CARRIER PROTEINS; CHOLESTEROL; CHOLESTEROL 7-ALPHA-HYDROXYLASE; CYCLOSPORINE; HYDROXYMETHYLGLUTARYL COA REDUCTASES; IMMUNOSUPPRESSIVE AGENTS; LIPOPROTEIN LIPASE; LIPOPROTEINS, HDL; LIVER; MALE; MUSCLE, SKELETAL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LDL; RECEPTORS, LIPOPROTEIN; RNA-BINDING PROTEINS; TRIGLYCERIDES;

EID: 0033929373     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH and Krieger M (1996) Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science (Wash DC) 271:518-520.
2. Apanay DC, Neylan JF, Ragab MS and Sgoutas DS (1994) Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation (Baltimore) 58:663-669.
3. Arnadottir M, Thysell H and Nilsson-Ehle P (1991) Lipoprotein levels and post-heparin lipase activities in kidney transplant recipients: Ciclosporin-versus non-ciclosporin-treated patients. Am J Nephrol 11:391-396.
4. Ballantyne CM, Podet EJ, Patsch WP, Harati Y, Appel V, Gotto AM Jr and Young JB (1989) Effects of cyclosporine therapy on plasma lipoprotein levels. J Am Med Assoc 262:53-56.
5. Cooper AD (1989) Hepatic lipoprotein and cholesterol metabolism, in Hepatology (Zakin D and Boyer T eds) pp 105-137, WB Saunders, Philadelphia.
6. Dietschy JM (1995) Experimental mechanism: Regulation of plasma LDL cholesterol. Am J Clin Nutr 62:679S-688S.
7. Drucke TB, Abdulmassih Z, Lacour B, Bader C, Chevalier A and Kreis H (1991) Atherosclerosis and lipid disorders after renal transplantation. Kidney Int Suppl 31:S24-S28.
8. Edwards BD, Bhatnagar D, Mackness MI, Gokal R, Ballardie FW, Chalmers RJ and Durrington PN (1995) Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis. QJM 88:109-113.
9. Jokinen EV, Landschulz KT, Wyne KL, Ho YK, Frykman PK and Hobbs JJ (19941 Regulation of the very low density lipoprotein receptor by thyroid hormone in rat skeletal muscle. J Biol Chem 269:26411-26418.
10. Kuster GM, Drexel H, Bleisch JA, Rentsch K, Pei P, Binswanger U and Amann FW (1994) Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation (Baltimore) 57:1479-1483.
11. Liang K and Vaziri ND (1997a) Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Int 51:1761-1765.
12. Liang K and Vaziri ND (1997b) Gene expression of lipoprotein lipase in experimental nephrosis. J Lab Clin Med 130:387-394.
13. Liang K and Vaziri ND (1999) Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome. Kidney Int 56:621-626.
14. Liang KH, Oveisi F and Vaziri ND (1996) Gene expression of hepatic cholesterol 7 alpha-hydroxylase in the course of puromycin-induced nephrosis. Kidney Int 49: 855-860.
15. Lopez-Miranda J, Vilella E, Perez-Jimenez F, Espino A, Jimenez-Pereperez JA, Masana L and Turner PP (1993) Low-density lipoprotein metabolism in rats treated with cyclosporine. Metabolism 42:678-683.
16. Oriji GK and Keiser HR (1998) Role of nitric oxide in cyclosporine A-induced hypertension. Hypertension 32:849-855.
17. Princen HM, Meijer P, Wolthers BG, Vonk RJ and Kuipers F (1991) Cyclosporin A blocks bile acid synthesis in cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis. Biochem J 275:501-505.
18. Raine AE, Carter R, Mann JI and Morris PJ (1988) Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrol Dial Transplant 3:458-463.
19. Rayyes OA, Wallmark A and Floren CH (1996) Cyclosporine inhibits catabolism of low-density lipoproteins in HepG2 cells by about 25%. Hepatology 24:613-619.
20. Roullet JB, Xue H, McCarron DA, Holcomb S and Bennett WM (1994) Vascular mechanisms of cyclosporin-induced hypertension in the rat. J Clin Invest 93:2244-2250.
21. Russell DW and Setchell KD (1992) Bile acid biosynthesis. Biochemistry 31:4737-4749.
22. Schorn TF, Kliem V, Bojanovski M, Bojanovski D, Repp H, Bunzendahl H and Frei U (1991) Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients. Transpl Int 4:92-95.
23. Sutherland WH, Walker RJ, Ball MJ, Stapley SA and Robertson MC (1995) Oxidation of low density lipoproteins from patients with renal failure or renal transplants. Kidney Int 48:227-236.
24. Takahashi S, Kawarabayasi Y, Nakai T, Sakai J and Yamamoto T (1992) Rabbit very low density lipoprotein receptor: A low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA 89:9252-9256.
25. Takahashi S, Suzuki J, Kohno M, Oida K, Tamai T, Miyabo S, Yamamoto T and Nakai T (1995) Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J Biol Chem 270:15747-15754.
26. Takenaka T, Hashimoto Y and Epstein M (1992) Diminished acetylcholine-induced vasadilation in renal microvessels of cyclosporine-treated rats. J Am Soc Nephrol 3:42-50.
27. Vaziri ND and Liang K (1995) Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 48:1979-1985.
28. Vaziri ND and Liang K (1996a) Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 50:1928-1935.
29. Vaziri ND and Liang K (1996b) Down-regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 50:887-893.
30. Vaziri ND and Liang K (1997) Down-regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int 51:913-919.
31. Vaziri ND, Ni Z, Zhang YP, Ruzics EP, Maleki P and Ding Y (1998) Depressed renal and vascular nitric oxide synthase expression in cyclosporine-induced hypertension. Kidney Int 54:482-491.
32. Vaziri ND, Wang XQ and Liang K (1997) Secondary hyperparathyroidism downregulates lipoprotem lipase expression in chronic renal failure. Am J Physiol 273: F925-F930.
33. Verpooten GA, Cools FJ, Van der Planken MG, Bedert LC, Claes R, Van Gaal LF and De Broe ME (1996) Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients. Nephrol Dial Transplant 11:347-351.
34. Verzola A, Bedani PL and Gilli P (1999) Effect of ciclosporin on triglyceridemia in long-term renal transplant recipients. Nephron 81:240-241.
35. Webb AT, Plant M, Reaveley DA, O'Donnell M, Luck VA, O'Connor B, Seed M and Brown EA (1992) Lipid and lipoprotein (a) concentrations in renal transplant patients. Nephrol Dial Transplant 7:636-641.